Clinical Trial News Archive - March 2025
March 1, 2025
March 2, 2025
March 3, 2025
- FDA Grants Orphan Drug Designation for Bexmarilimab in MDS
- Omalizumab Treats Multi-Food Allergy Better Than Oral Immunotherapy
- Latigo Biotherapeutics Granted FDA Fast Track Designation for LTG-001 for the Non-Opioid Treatment of Acute Pain
- Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
March 4, 2025
March 5, 2025
- NIH-Funded Research Team Engineers New Drug Targeting Pain Sensation Pathway
- Novo Nordisk Introduces NovoCare® Pharmacy, Lowering Cost of All Doses of FDA-Approved Wegovy® (semaglutide) to $499 per Month
- Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF
March 6, 2025
- Tris Pharma Announces Positive Results from ALLEVIATE-2 Phase 3 Pivotal Trial for Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of Moderate-to-Severe Acute Pain
- Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer
March 7, 2025
March 8, 2025
- Amgen and Kyowa Kirin Provide Top-Line Results from Rocatinlimab Phase 3 Ignite Study in Adults with Moderate to Severe Atopic Dermatitis
- Icotrokinra Results Show Potential to Set a New Standard of Treatment in Plaque Psoriasis
- Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata
March 10, 2025
- Icotrokinra Meets Primary Endpoint of Clinical Response in Ulcerative Colitis Study and Shows Potential to Transform the Treatment Paradigm for Patients
- CagriSema Demonstrates Superior Weight Loss in Adults with Obesity or Overweight and Type 2 Diabetes in the REDEFINE 2 Trial
March 11, 2025
- Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate
- Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
- Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
- First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
March 12, 2025
March 13, 2025
- Tecovirimat is Safe But Ineffective as Treatment for Clade II Mpox
- ViiV Healthcare’s Investigational Broadly Neutralising Antibody - N6LS - Successfully Maintains Viral Suppression in Long-Acting Treatment of HIV
- SCORPIO-PEP Phase 3 Trial: Ensitrelvir is the First and Only COVID-19 Oral Antiviral to Demonstrate Prevention of COVID-19 as Post Exposure Prophylaxis
- Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults
March 14, 2025
- Topical Steroid Withdrawal Diagnostic Criteria Defined by NIH Researchers
- Sanofi Adopts FDA-Selected Flu Strains to Ensure Readiness for the 2025-26 Flu Season
- KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency
- Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600
March 15, 2025
March 17, 2025
- PEP-Therapy Receives FDA Orphan Drug Designation for PEP-010 for Treatment of Pancreatic Cancer
- Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa
- GRIN Therapeutics Receives FDA Orphan Drug Designation for Radiprodil for the Treatment of GRIN-Related Neurodevelopmental Disorder
- NIH-Sponsored Trial of Lassa Vaccine Opens
- Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia
- Surgery in Kids with Mild Sleep-Disordered Breathing Tied to Fewer Doctor Visits, Meds
- NIH-Funded Study Identifies Potential New Stroke Treatment
- Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer
- Eneboparatide Met Primary Endpoint of Normalising Serum Calcium in Adults with Hypoparathyroidism at 24 weeks in CALYPSO Phase III Trial
- BioArctic Receives Orphan Drug Designation for Exidavnemab the US
- vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes
March 18, 2025
- Nipocalimab, the First and Only Investigational Treatment to be Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of Adults with Moderate-to-Severe Sjögren’s Disease, has now Received Fast Track Designation
- Signal12 Achieves FDA Alignment, Accelerating Pro-ocular™ Towards Phase 3 Clinical Trials for Ocular Graft-versus-Host Disease
- Sarepta Therapeutics Shares Safety Update on Elevidys
- FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient
March 19, 2025
- Azer-cel Granted FDA Fast Track Designation in Blood Cancer DLBCL
- Henlius Receives Orphan-Drug Designation for HLX22 (Innovative anti-HER2 mAb) in the U.S. for Gastric Cancer
- Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
- New Data on Investigational Therapy Doxecitine and Doxribtimine for Thymidine Kinase 2 Deficiency Presented at Muscular Dystrophy Association (MDA) 2025 Conference
March 21, 2025
- Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program
- NIH Researchers Develop Eye Drops That Slow Vision Loss in Animals
March 24, 2025
March 25, 2025
March 26, 2025
March 27, 2025
March 29, 2025
March 30, 2025
March 31, 2025
Clinical trial results archive
- 2025
- January, February, March, April, May
- 2024
- January, February, March, April, May, June, July, August, September, October, November, December
- 2023
- January, February, March, April, May, June, July, August, September, October, November, December
- 2022
- January, February, March, April, May, June, July, August, September, October, November, December
- 2021
- January, February, March, April, May, June, July, August, September, October, November, December
- 2020
- January, February, March, April, May, June, July, August, September, October, November, December
- 2019
- January, February, March, April, May, June, July, August, September, October, November, December
- 2018
- January, February, March, April, May, June, July, August, September, October, November, December
- 2017
- May, June, July, August, September, October, November, December
- 2016
- October
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.